Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.
Mainz Biomed N.V. (NASDAQ:MYNZ) shares began Tuesday in the red, as the Berkeley, Calif.-based company, a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to announce its upcoming participation at the 39th UDH Congress .
Mainz Biomed (NASDAQ:MYNZ – Free Report) had its target price decreased by HC Wainwright from $5.00 to $3.00 in a research note published on Wednesday, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2024 earnings at ($0.18) EPS and FY2024 earnings at […]
Mainz Biomed (NASDAQ:MYNZ – Free Report) had its price target cut by HC Wainwright from $5.00 to $3.00 in a research report report published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Mainz Biomed’s Q4 2024 earnings at ($0.18) EPS and FY2024 earnings […]
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track record at treating. At the end of last year, Merck (NYSE: MRK) provided a non-optimistic update regarding its Phase 3 LEAP-001 trial that evaluates a combined treatment that uses its blockbuster cancer drug, Keytruda, against advanced endometrial carcinoma. The failure of Merck to improve the treat